SCHEMBL23693702

SCHEMBL23693702

COC(=O)c1cc(Oc2ccnc(NCc3ccc(OC)cc3OC)c2F)c(F)c(F)c1Nc1ccc(I)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.41
▸ MAP2K1 Q02750 12/20 0.40
▸ KDM4C Q9H3R0 1/20 0.39
▸ ERBB2 P04626 1/20 0.38
▸ PRKACA P17612 1/20 0.38
▸ RPS6KB1 P23443 1/20 0.38
▸ GSK3A P49840 1/20 0.38
▸ GSK3B P49841 1/20 0.38
▸ IRAK1 P51617 1/20 0.38
▸ RPS6KA3 P51812 1/20 0.38
▸ ROCK1 Q13464 1/20 0.38
▸ CDC42BPA Q5VT25 1/20 0.38
▸ AURKB Q96GD4 1/20 0.38
▸ CSNK1G3 Q9Y6M4 1/20 0.38
▸ CYP1A2 P05177 3/20 0.37
▸ CYP3A4 P08684 3/20 0.37
▸ CYP2C19 P33261 3/20 0.37
▸ USP2 O75604 2/20 0.37
▸ TSHR P16473 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29781404 1.00 MAPT (0.41) MAPTMAP2K1KDM4CERBB2PRKACA
SCHEMBL30172479 1.00 MAPT (0.41) MAPTMAP2K1KDM4CERBB2PRKACA
SCHEMBL27224635 0.94 KDM4C (0.45) MAPTMAP2K1KDM4CERBB2PRKACA
SCHEMBL30866578 0.94 KDM4C (0.45) MAPTMAP2K1KDM4CERBB2PRKACA
SCHEMBL23693705 0.92 MAPT (0.43) MAPTKDM4CERBB2PRKACARPS6KB1
SCHEMBL30080297 0.88 MAP2K1 (0.43) MAPTMAP2K1KDM4CERBB2PRKACA
SCHEMBL23694115 0.88 MAP2K1 (0.43) MAPTMAP2K1KDM4CERBB2PRKACA
SCHEMBL25720467 0.86 ERBB2 (0.36) MAPTMAP2K1KDM4CERBB2PRKACA
SCHEMBL31401592 0.82 MAPT (0.44) MAPTKDM4CERBB2PRKACARPS6KB1
SCHEMBL38651248 0.82 MAPT (0.44) MAPTKDM4CERBB2PRKACARPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230270730-A1 COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-08-31 — — US disclosed
WO-2023003014-A1 METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE 中外製薬株式会社 2023-01-26 — — WO disclosed
US-20230002333-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-01-05 — — US disclosed
WO-2021149776-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY 中外製薬株式会社 2021-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230270730-A1 COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE BRAF, NRAS, KRAS MAPT 1620/4885MAP2K1 17/4885KDM4C 777/4885
US-20230002333-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY BRAF, NRAS, KRAS MAPT 4690/4885MAP2K1 162/4885KDM4C 1698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback